Publications of Eve LEBAS
Bookmark and Share    
Full Text
See detailA Comprehensive Update of the Atypical, Rare and Mimicking Presentations of Mycosis Fungoides
LEBAS, Eve ULiege; COLLINS, Patrick ULiege; SOMJA, Joan ULiege et al

in Dermatology and Therapy (2021)

Introduction: Mycosis fungoides (MF) is the most frequent subtype of primary cutaneous T cell lymphomas (pCTCL). The diagnosis may be particularly difficult in the early stages as well as in atypical and ... [more ▼]

Introduction: Mycosis fungoides (MF) is the most frequent subtype of primary cutaneous T cell lymphomas (pCTCL). The diagnosis may be particularly difficult in the early stages as well as in atypical and rare clinical presentations. Furthermore, MF may simulate a large variety of common dermatologic disorders and patterns, both histopathologically and clinically. Methods: A literature search was performed to provide a comprehensive update on the rare and atypical MF manifestations as well as the dermatoses and dermatological patterns that could be imitated by MF. Results: A total of 114 publications were found describing a series of different dermatoses and dermatological patterns mimicked by MF, as well as some particular localizations of MF lesions and dermatoses that occur in preexisting MF lesions. Conclusions: The number of dermatoses that can be imitated by MF is ever-increasing. Patients with common dermatologic conditions that prove to be treatment refractory should be biopsied without delay, and sequentially as necessary, to prevent delay in diagnosis and progression of disease. Clinicopathologic correlation is the best way of diagnosis. [less ▲]

Detailed reference viewed: 26 (4 ULiège)
Full Text
See detailLe phénomène de Köbner en Dermatologie
GIET, Gabrielle ULiege; SENTERRE, Yseult ULiege; LEBAS, Eve ULiege et al

in Revue Médicale de Liège (2021), 76(9), 651-656

Köbner's phenomenon and its related phenomena are dermatological curiosities that are still partially misunderstood. The Köbner phenomenon is by far the best known and the most studied. It is ... [more ▼]

Köbner's phenomenon and its related phenomena are dermatological curiosities that are still partially misunderstood. The Köbner phenomenon is by far the best known and the most studied. It is characterized as the appearance of an inflammatory or infectious dermatosis in an area of healthy skin after skin trauma. The dermatoses most frequently concerned are psoriasis, lichen planus and vitiligo. The inverse Köbner phenomenon and the Renbök phenomenon are two very similar phenomena. The first represents the disappearance of a skin lesion after skin trauma. The second is characterized by a skin trauma that is more specifically induced by another dermatosis. Finally, the Wolf's isotopic phenomenon corresponds to the appearance of a new dermatosis on an area of the skin that was previously the site of another healed dermatosis. [less ▲]

Detailed reference viewed: 23 (2 ULiège)
Full Text
See detailBiologicals for moderate-to-severe plaque type psoriasis in pediatric patients
Libon, Florence ULiege; LEBAS, Eve ULiege; DE SCHAETZEN VAN BRIENEN, Virginie ULiege et al

in Expert Review of Clinical Immunology (2021), 17

Introduction Psoriasis affects around 2% of children in Europe. The majority of cases is readily managed with topical treatments using corticosteroids without or with calcipotriol. More resistant and ... [more ▼]

Introduction Psoriasis affects around 2% of children in Europe. The majority of cases is readily managed with topical treatments using corticosteroids without or with calcipotriol. More resistant and extensive moderate-to-severe cases require UVA or UVB phototherapies or conventional systemic treatment including ciclosporin, acitretin and methotrexate. However, these therapies are associated with a low tolerability and potential cumulative long-term adverse effects and toxicities. Areas covered About 15 years ago, the first biological appeared for the treatment of moderate-to-severe plaque type psoriasis in adult patients. Several years later, the first biologic treatment to be approved in children was etanercept, a soluble receptor that binds both tumor necrosis factor (TNF)-α and β followed by adalimumab, a monoclonal antibody against TNF-α, and currently by ustekinumab, a monoclonal IL12/23 p40 antagonist and, very recently, secukinumab and ixekizumab, both IL17 antagonists. All these biologic treatments brought significantly improved treatment results compared to light-based therapies and conventional treatments and present very good tolerance and safety profiles. Expert opinion Due to their excellent efficacy and safety profiles ustekinumab, secukinumab and ixekizumab could currently be considered as a first-line treatment options for moderate-to-severe childhood and adolescent psoriasis requiring a systemic treatment. [less ▲]

Detailed reference viewed: 21 (1 ULiège)
Full Text
See detailComment je traite… le mycosis fongoïde : à propos du brentuximab védotine, une nouvelle arme thérapeutique
LEBAS, Eve ULiege; COLLINS, Patrick ULiege; BONNET, Christophe ULiege et al

in Revue Médicale de Liège (2021), 76(4), 224-231

Récemment, le brentuximab védotine (BV) (Adcetris®) a obtenu le remboursement en Belgique pour le traitement du lymphome cutané primitif de type mycosis fongoïde (MF), du lymphome anaplasique à larges ... [more ▼]

Récemment, le brentuximab védotine (BV) (Adcetris®) a obtenu le remboursement en Belgique pour le traitement du lymphome cutané primitif de type mycosis fongoïde (MF), du lymphome anaplasique à larges cellules et de la papulose lymphomatoïde de type A. Le BV est un anticorps monoclonal dirigé contre le CD30 exprimé par les cellules T tumorales. L’inhibition de cette voie de signalisation induit un processus d’apoptose et conduit à la mort cellulaire. Le BV est remboursé après l’échec d’un autre traitement systémique et lorsque le nombre de cellules T atypiques exprimant le CD30 en immunohistochimie excède 10 % de la population totale sur une biopsie cutanée. Le BV est administré par voie intraveineuse toutes les 3 semaines à la posologie de 1,8 mg/kg, avec un maximum de 16 cures. Les taux de réponse globale excèdent 75 %. Certains patients négatifs pour le CD30 ont également montré une réponse thérapeutique intéressante. Les principaux effets indésirables du BV sont la neutropénie et la neuropathie périphérique. Les cas de deux patients avec un MF de longue date et multi-résistant, ayant répondu favorablement au BV, sont présentés dans cet article. [less ▲]

Detailed reference viewed: 37 (6 ULiège)
Full Text
See detailCutaneous Breast Cancer Metastases Successfully Treated Using an Oxygen Flow Assisted Topical Administration of Methotrexate (OFAMTX)
Jouret, Gaëlle ULiege; GONNE, Elodie ULiege; QUATRESOOZ, Pascale ULiege et al

in Dermatology and Therapy (2020)

Cutaneous metastases of breast cancer remain a therapeutic challenge. Oxygen flow-assisted topical administration of methotrexate 5% (OFAMTX, 5% methotrexate in a carrier solution) has recently been ... [more ▼]

Cutaneous metastases of breast cancer remain a therapeutic challenge. Oxygen flow-assisted topical administration of methotrexate 5% (OFAMTX, 5% methotrexate in a carrier solution) has recently been proven to be an efficacious alternative treatment for extramammary Paget’s disease, which is considered to be an in situ mammary adenocarcinoma of the epidermis. [less ▲]

Detailed reference viewed: 61 (5 ULiège)
Full Text
See detailLes traitements actuels du psoriasis : de l’étanercept aux antagonistes anti-IL17 et -IL23
Libon, Florence ULiege; LEBAS, Eve ULiege; EL HAYDERI, Lara ULiege et al

in Revue Médicale de Liège (2020), 75(5-6), 376-381

Psoriasis is a chronic inflammatory skin disease affecting around 2-3 % of the population. The disease spectrum evolves from to the knees and elbows limited disease to erythrodermic psoriasis. The impact ... [more ▼]

Psoriasis is a chronic inflammatory skin disease affecting around 2-3 % of the population. The disease spectrum evolves from to the knees and elbows limited disease to erythrodermic psoriasis. The impact on the quality of life, the pruritus, the pain from palmo-plantar disease, arthropathic psoriasis and the comorbidities are the major complaints of the patients. The treatment relies on topical treatments with dermocorticosteroids with or without vitamin D derivatives, UVA or UVB phototherapy, conventional treatments including methotrexate, ciclosporin and acitretin, and, since around 15 years, biological treatments. The biological treatments for moderate to severe psoriasis progressed in a spectacular way with an improvement of clinical results and an amelioration of the safety profile at every step. This article discusses these developments from the TNFα antagonists, including etanercept, adalimumab and infliximab to the newly arrivals, the anti-IL17 and anti- IL23 antagonists, the anti-PDE-4 antagonists and the JAK inhibitors. [less ▲]

Detailed reference viewed: 95 (11 ULiège)
Full Text
See detailExploratory Assessment of Oxygen Flow–Assisted Cutaneous Administration of Methotrexate for Superficial Basal Cell Carcinoma, Mycosis Fungoides, and Extramammary Paget Disease
LEBAS, Eve ULiege; CHAPELIER, Corinne ULiege; QUATRESOOZ, Pascale ULiege et al

in Journal of Investigative Dermatology (2019), 140(3), 583-592

The molecular weight of methotrexate (MTX) makes cutaneous penetration difficult. Oxygen flow could enhance the skin permeation of MTX diluted in the proprietary LP3 carrier system. This pilot study aims ... [more ▼]

The molecular weight of methotrexate (MTX) makes cutaneous penetration difficult. Oxygen flow could enhance the skin permeation of MTX diluted in the proprietary LP3 carrier system. This pilot study aims to assess the efficacy, safety, and tolerance of oxygen flow-assisted LP3-MTX3% for treating superficial skin cancers. Patients with superficial basal cell carcinoma (n = 12), extramammary Paget disease (n = 5), classic mycosis fungoides (MF; n = 10), and folliculotropic MF (n = 6) were included in the study and were treated with four weekly applications of oxygen flow-assisted LP3-MTX3%. Photographs and biopsies were performed before and one month after treatment. At one month after treatment, the mean superficial basal cell carcinoma erythema-crusting-thickness clinical score, the extramammary Paget disease erythema-oozing-scaling/hyperkeratosis-pain/pruritus clinical score, and the modified composite assessment of index lesion severity classic MF and folliculotropic MF scores were improved by 77.5% ± 17.1% (P < 0.0001), 66.7% ± 22.9% (P = 0.011), 51.3% ± 32.2% (P = 0.0007), and 27.8% ± 32.0% (P = 0.086), respectively. At one month after treatment, histology revealed partial and total clearances for superficial basal cell carcinoma (1/12, 11/12), extramammary Paget disease (4/5, 1/5), classic MF (8/10, 2/10), and folliculotropic MF (6/6, 0/6). Tolerance was excellent and no pain was observed. MTX was never detectable in serum at baseline and 1, 2, 3, 8, 24, 48, and 72 hours post-treatment. In conclusion, the interesting therapeutic efficacy of oxygen flow-assisted LP3-MTX3% for treating superficial basal cell carcinoma, extramammary Paget disease, and MF lesions prompts further studies on a larger scale. Copyright © 2019 The Authors. [less ▲]

Detailed reference viewed: 17 (1 ULiège)
Full Text
See detailSimultaneous condylomata acuminata and squamous cell carcinoma of the penis with different HPV genotypes
LEBAS, Eve ULiege; DORMAL, Martin ULiege; Herfs, Michael ULiege et al

in European Journal of Dermatology (2019), 29(4), 433-435

Penile cancer occurs predominantly in elderly men and is associated with a high morbidity and mortality rate. Invasive penile squamous cell cancer (pSCC) accounts for around 90% of all penile cancers ... [more ▼]

Penile cancer occurs predominantly in elderly men and is associated with a high morbidity and mortality rate. Invasive penile squamous cell cancer (pSCC) accounts for around 90% of all penile cancers. pSCC is associated in about40%of the cases with the presence of high-risk human papillomaviruses (HR-HPV), in particular, the oncogenic genotypes. In general, in less differentiated SCC, the incidence of HR-HPV is lower than in well differentiated SCC. [less ▲]

Detailed reference viewed: 47 (7 ULiège)
Full Text
See detailComment je traite... Les toxicités mucocutanées des thérapies ciblées en oncologie
DAMSIN, Thomas ULiege; COLLIGNON, Joëlle ULiege; LEBAS, Eve ULiege et al

in Revue Médicale de Liège (2019), 01

Le spectre des effets indésirables mucocutanés des thérapies ciblées (hors immunothérapies), comme les anti-EGFR, anti-VEGF, anti-TK et anti-BRAF, présente des similarités avec celui des traitements ... [more ▼]

Le spectre des effets indésirables mucocutanés des thérapies ciblées (hors immunothérapies), comme les anti-EGFR, anti-VEGF, anti-TK et anti-BRAF, présente des similarités avec celui des traitements chimiothérapeutiques classiques, mais également des lésions plus spécifiques. Cet article abordera les toxicités dermatologiques des thérapies ciblées, à l'aide de 11 illustrations cliniques : les mucites et toxicités endobuccales, les éruptions acnéiformes, les modifications et complications unguéales, le syndrome main/pied, la radiosensibilisation, les alopécies, la xérose et les fissures cutanées. Après une brève description clinique et quelques notions théoriques, la prise en charge dermatologique est détaillée. [less ▲]

Detailed reference viewed: 204 (16 ULiège)
Full Text
See detailGranulomatous reactions from tattoos following BRAF inhibitor therapy
GIET, Gabrielle ULiege; LEBAS, Eve ULiege; RORIVE, Andrée ULiege et al

in Case Reports in Dermatology (2019), 11

Detailed reference viewed: 52 (5 ULiège)
Full Text
See detailPatient avec un carcinome spinocellulaire cutané localement avancé et métastatique traité par Cemiplimab
Vanhakendover, Louise ULiege; LEBAS, Eve ULiege; Libon, Florence ULiege et al

in Revue Médicale de Liège (2019), (74), 1-5

Le traitement du carcinome spinocellulaire cutané (cSCC) localement avancé et/ou métastasique repose essentiellement sur la chirurgie et, éventuellement, une radiothérapie de la zone chirurgicale et de ... [more ▼]

Le traitement du carcinome spinocellulaire cutané (cSCC) localement avancé et/ou métastasique repose essentiellement sur la chirurgie et, éventuellement, une radiothérapie de la zone chirurgicale et de l’aire ganglionnaire afférente. Malheureusement, certains cas ne sont plus opérables ou accessibles à la radiothérapie et un traitement systémique est alors indiqué. Les chimiothérapies sont peu efficaces et potentiellement toxiques. Une étude récente évaluant l’efficacité et la tolérance du cemiplimab, un antagoniste PD1, dans les cSCC localement avancés et métastasiques démontre une réponse objective confirmée de 49 % et de 47 %, respectivement, avec un maintien de la réponse d’au moins 6 mois de 63 % et de 60 %, respectivement. Nous présentons le cas d’un patient avec un cSCC localement avancé au niveau du front, avec effraction osseuse et adénopathies cervicales, ayant eu de multiples chirurgies et radiothérapies. Il a présenté une réponse partielle au cemiplimab avec un profil de tolérance satisfaisant. [less ▲]

Detailed reference viewed: 122 (7 ULiège)
Full Text
See detailCarcinome spinocellulaire cutané localement avancé et métastatique traité par cemiplimab.
Vanhakendover, Louise ULiege; LEBAS, Eve ULiege; Libon, Florence ULiege et al

in Revue medicale de Liege (2019), 74(7-8), 436-440

The treatment of locally advanced or metastatic cutaneous squamous cell carcinoma (cSCC) essentially relies on surgery and eventually radiotherapy of the treated site and afferent lymph nodes ... [more ▼]

The treatment of locally advanced or metastatic cutaneous squamous cell carcinoma (cSCC) essentially relies on surgery and eventually radiotherapy of the treated site and afferent lymph nodes. Unfortunately, some cases are no candidates for surgery or radiotherapy and a systemic treatment may be indicated. Chemotherapies are only partially efficacious and associated with potential toxicities. A recent study evaluating the efficacy and tolerance of cemiplimab, a PD1 antagonist for locally advanced and metastatic cSCC demonstrated an objective response rate of 49 % and 47 % for locally advanced and metastatic cSCC, while maintaining a response of at least 6 months of 63 % and 60 %, respectively. We present a clinical case of a patient with a locally advanced cSCC of the forehead with bone resorption and cervical lymphadenopathies. After failure of multiple surgical interventions and radiotherapies, he responded partially to cemiplimab immunotherapy with a good safety profile. [less ▲]

Detailed reference viewed: 214 (20 ULiège)
Full Text
See detailSensibilisation immédiate aux moisissures et aux levures chez les patients souffrant de maladies respiratoires allergiques (AR) par rapport à ceux atteints de dermatite atopique de la tête au cou (DA)
DEZFOULIAN, Bita ULiege; LEBAS, Eve ULiege; NIKKELS, Arjen ULiege

in Revue Francaise d'Allergologie (2018)

Les moisissures et/ou les levures peuvent jouer un rôle important dans l'induction des poussées et de la persistance de la DA et de l'AR. Nous avons voulu déterminer les taux de sensibilisation aux ... [more ▼]

Les moisissures et/ou les levures peuvent jouer un rôle important dans l'induction des poussées et de la persistance de la DA et de l'AR. Nous avons voulu déterminer les taux de sensibilisation aux moisissures et aux levures chez les patients atteints d'AR par rapport à ceux atteints de DA, qui ont consulté notre service, durant une année. [less ▲]

Detailed reference viewed: 17 (5 ULiège)
Full Text
See detailQuoi de neuf dans le traitement de l'hidradénite suppurative en 2018?
GIET, Gabrielle ULiege; LEBAS, Eve ULiege; Libon, Florence ULiege et al

in Revue Médicale de Liège (2018)

Hidradenitis suppurativa (HS), also known as Verneuil’s disease and acne inversa, is a chronic inflammatory skin disease characterized by a dysfunction of the pilosebaceous structures resulting in ... [more ▼]

Hidradenitis suppurativa (HS), also known as Verneuil’s disease and acne inversa, is a chronic inflammatory skin disease characterized by a dysfunction of the pilosebaceous structures resulting in occlusion and inflammation. The disease usually starts after puberty, on average between twenty and thirty years, with subcutaneous painful inflammatory nodules, abscess collections, fistulization and scars mainly in the axillary, inguinal, sub-mammary, perineal and perianal regions. It is a multifactorial disease with the most commonly cited risk factors or aggravating factors being smoking, obesity, and HS family history. The first line of treatment relies on antibiotics, including tetracyclins, clindamycin and rifampycin. In case of non-response, TNFα antagonists, more specifically adalimumab, may be considered. [less ▲]

Detailed reference viewed: 262 (9 ULiège)